{"id":25071,"date":"2025-06-09T12:43:32","date_gmt":"2025-06-09T05:43:32","guid":{"rendered":"https:\/\/thaipropertynews.com\/feeds\/?p=25071"},"modified":"2025-06-09T12:43:32","modified_gmt":"2025-06-09T05:43:32","slug":"early-chronic-kidney-disease-ckd-intervention-could-save-australia-1-billion-a-year1","status":"publish","type":"post","link":"https:\/\/thaipropertynews.com\/feeds\/?p=25071","title":{"rendered":"EARLY CHRONIC KIDNEY DISEASE (CKD) INTERVENTION COULD SAVE AUSTRALIA $1 BILLION A YEAR[1]"},"content":{"rendered":"

SYDNEY<\/span>, June 7, 2025<\/span> \/PRNewswire\/ —\u00a0New modelling highlights the potential societal, economic and environmental benefits of early chronic kidney disease (CKD) intervention which could change lives for thousands of Australians.<\/p>\n

Australia could save $25.2 billion in CKD-related\u00a0costs and\u00a0more\u00a0than halve dialysis demand over 25 years with early action.1<\/sup> The model projects additional gains for the Australian economy\u00a0and\u00a0society with\u00a0projections\u00a0showing a\u00a0$1.6\u00a0billion\u00a0increase\u00a0in\u00a0net\u00a0tax\u00a0revenue\u00a0could be achieved over the same period and 200,000 more people in the workforce.1<\/sup><\/p>\n

An\u00a0estimated\u00a02.7\u00a0million\u00a0people in\u00a0Australia\u00a0are\u00a0currently\u00a0living with\u00a0signs\u00a0of\u00a0CKD.2<\/sup>\u00a0The\u00a0disease costs the Australian economy at least $9.9 billion a year.3<\/sup><\/p>\n

Newly published findings from\u00a0the\u00a0IMPACT CKD\u00a0modelling\u00a0analysis by AstraZeneca\u00a0suggest that policy measures targeting CKD could unlock wide-ranging societal benefits across Australia.\u00a0With\u00a0early\u00a0action pressure\u00a0can\u00a0be\u00a0eased\u00a0on\u00a0the\u00a0healthcare\u00a0system,\u00a0driving\u00a0economic productivity while improving the lives of people living with CKD.<\/p>\n

The\u00a0IMPACT\u00a0CKD\u00a0simulation\u00a0modelled outcomes\u00a0for\u00a0the\u00a0Australian\u00a0population\u00a0over\u00a0a\u00a025-year period, from 2022 to 2047, to explore the potential impact of early intervention.1<\/sup> It assessed the combined effect of earlier detection, diagnosis, and better access to treatment including annual targeted testing for high-risk individuals and improved use of guideline-directed medical therapy (GDMT).<\/p>\n

The modelling projected\u00a0significant improvements\u00a0in health\u00a0outcomes in Australia including\u00a0a 48.1% decrease in cardiovascular (CV) events and a 7.3% decrease in all-cause mortality over\u00a025\u00a0years.1<\/sup>\u00a0These outcomes\u00a0were\u00a0accompanied\u00a0by\u00a0a\u00a055%\u00a0projected\u00a0reduction\u00a0in\u00a0dialysis, one of the most resource-intensive treatment options in CKD care.1<\/sup> As a result, CKD-related healthcare costs in Australia\u00a0are projected to decrease by 10.9%,\u00a0resulting\u00a0in an estimated<\/p>\n

$25.2\u00a0billion in\u00a0savings\u00a0over\u00a0the\u00a0same\u00a0period.1<\/sup><\/p>\n

Beyond the clinical and economic implications, the modelling also indicated that reducing reliance on dialysis could cut kidney replacement therapy (KRT)-related freshwater consumption by\u00a051.0%,\u00a0fossil fuel\u00a0use\u00a0by\u00a048.2%,\u00a0and\u00a0carbon\u00a0emissions by\u00a048.1%1<\/sup>\u00a0–\u00a0delivering meaningful\u00a0environmental\u00a0benefits that\u00a0align\u00a0with\u00a0the\u00a0Australian\u00a0Government’s\u00a0National\u00a0Health and Climate Strategy.<\/p>\n

Ben McDonald, Country President of AstraZeneca Australia and New Zealand, said the findings\u00a0demonstrate\u00a0the\u00a0opportunity\u00a0we\u00a0have\u00a0in\u00a0Australia\u00a0to\u00a0reduce\u00a0the\u00a0health\u00a0and\u00a0economic burden of CKD.<\/p>\n

“Earlier\u00a0access to\u00a0diagnosis\u00a0and\u00a0treatment\u00a0improves outcomes\u00a0for\u00a0patients, can\u00a0slow\u00a0renal progression and help avoid dialysis costs. With the right focus and investment, we can create system-wide benefits for people, society and the planet, Mr McDonald said.<\/p>\n

“Increa<\/span>sing\u00a0the\u00a0early\u00a0detection\u00a0and\u00a0treatment\u00a0of\u00a0CKD\u00a0in\u00a0Australia\u00a0needs\u00a0to\u00a0be\u00a0a\u00a0public health priority. The Australian health system can do more to work with people who are at high risk of having CKD but may not know it.”<\/p>\n

Chris\u00a0Forbes,\u00a0CEO\u00a0of\u00a0Kidney\u00a0Health Australia\u00a0(KHA),\u00a0welcomed the\u00a0findings.<\/p>\n

“Early diagnosis\u00a0can\u00a0make a life-changing difference for Australians living\u00a0with CKD. It’s\u00a0time to\u00a0turn\u00a0off\u00a0the\u00a0tap.\u00a0Early\u00a0detection\u00a0provides\u00a0patients\u00a0the\u00a0best\u00a0opportunity\u00a0to\u00a0treat\u00a0the\u00a0disease – slowing or even stopping progression to kidney failure, and avoiding the significant toll of dialysis, Mr Forbes said.<\/p>\n

“Too many people are slipping through the cracks until it’s too late. Our ambition is a future where every Australian has the ability to enjoy excellent kidney health. We urgently need policy action to support earlier detection and timely access to treatment.”<\/p>\n

NOT<\/span>ES TO EDITORS<\/u> <\/b> <\/p>\n

IMPACT CKD is the first study to examine and forecast the vast impact of CKD over a 25- year\u00a0time\u00a0horizon.1<\/sup>\u00a0It is\u00a0based\u00a0on\u00a0a\u00a0conceptual\u00a0disease\u00a0framework\u00a0developed\u00a0by\u00a0researchers at the London School of Economics in consultation with over 60 international and Australian experts. IMPACT CKD is part of AstraZeneca’s aim to improve the understanding and outcomes of CKD worldwide. AstraZeneca and\u00a0the Global Patient Alliance for Kidney Health (GloPAKH) launched ‘Make the Change for Kidney Health’<\/a> campaign to educate policy makers and health system leaders. This initiative seeks to elevate CKD on the global policy agenda, advocating for comprehensive and effective disease management strategies to combat this escalating health challenge.<\/p>\n

The new IMPACT CKD findings come just days after the World Health Assembly adopted a new\u00a0resolution\u00a0recognising\u00a0CKD\u00a0as\u00a0a\u00a0global public\u00a0health\u00a0priority which\u00a0is\u00a0a\u00a0critical\u00a0milestone that elevates CKD to the level of other major non-communicable diseases such as cancer, cardiovascular disease, and diabetes.4<\/sup><\/p>\n

About\u00a0CKD<\/b> <\/p>\n

CKD\u00a0is\u00a0a\u00a0silent disease\u00a0until\u00a0a\u00a0late\u00a0stage.5<\/sup>\u00a0Nearly\u00a0850\u00a0million people worldwide6<\/sup>, and\u00a0an estimated 2.7 million people in Australia have biomarkers of CKD, with 2.5 million<\/p>\n

Australians undiagnosed and unaware they have signs of the disease.2<\/sup> The most common causes\u00a0of\u00a0CKD\u00a0include\u00a0diabetes and\u00a0hypertension.\u00a0CKD\u00a0is\u00a0associated\u00a0with\u00a0significant\u00a0patient morbidity and an increased risk of cardiovascular events, such as myocardial infarction and heart failure (HF), which drives premature death.7<\/sup> In its most severe form, known as kidney failure, kidney damage and deterioration of kidney function have progressed to the point where dialysis or kidney transplantation are required. CKD patients are more likely to die of CV disease than to progress to end stage kidney disease.8<\/sup><\/p>\n

\n\n\n\n\n\n\n\n\n\n\n\n\n\n
<\/td>\n<\/tr>\n
\n

References<\/b> <\/span> <\/p>\n<\/td>\n<\/tr>\n

\n

1.\u00a0Tangri\u00a0N,\u00a0et\u00a0al.\u00a0Impact of\u00a0improved\u00a0diagnosis\u00a0and\u00a0treatment\u00a0on\u00a0holistic\u00a0chronic kidney\u00a0disease\u00a0burden. Kidney Int Rep<\/i>. 2025. In press. Journal Pre-proof. doi:10.1016\/j.ekir.2025.05.039.<\/span> <\/p>\n<\/td>\n<\/tr>\n

\n

2. ABS\u00a0National\u00a0Health\u00a0Measures Survey,\u00a0https:\/\/www.abs.gov.au\/statistics\/health\/health-conditions-and-<\/a><\/u>\u00a0risks\/national-health-measures-survey\/2022-24<\/a><\/u>\u00a0viewed\u00a030\u00a0May\u00a02025,\u00a0and\u00a0Kidney Health\u00a0Australia,\u00a0Media Release, ‘Kidney Disease Crisis: 2.7 million Australians Affected, 7 April 2025.<\/span> <\/p>\n<\/td>\n<\/tr>\n

\n

3.\u00a0Kidney\u00a0Health\u00a0Australia\u00a0and\u00a0Deloitte\u00a0Access Economics, Changing\u00a0the\u00a0chronic kidney\u00a0disease\u00a0landscape:\u00a0The economic benefits of early detection and treatment<\/i>, February 2023, https:\/\/kidney.org.au\/get-<\/a><\/u>\u00a0involved\/advocacy\/deloittereport<\/a>, <\/u>viewed 30 May 2025.<\/span> <\/p>\n<\/td>\n<\/tr>\n

\n

4.\u00a0World Health Organization (WHO). Seventy-eighth World Health Assembly \u2013 Daily update: 23 May 2025. Available\u00a0from:\u00a0https:\/\/www.who.int\/news\/item\/23-05-2025-seventy-eighth-world-health-assembly—daily-update–<\/a><\/u>\u00a023-may-2025,<\/u><\/a><\/u> viewed 30 May 2025.<\/span> <\/p>\n<\/td>\n<\/tr>\n

\n

5.\u00a0Whaley-Connell\u00a0A,\u00a0et\u00a0al.\u00a0The\u00a0importance\u00a0of\u00a0early identification\u00a0of\u00a0chronic kidney\u00a0disease.\u00a0Mo\u00a0Med.\u00a02011\u00a0Jan- Feb;108(1):25\u20138. PMID: 21462606; PMCID: PMC6188457.<\/span> <\/p>\n<\/td>\n<\/tr>\n

\n

6.\u00a0Jager\u00a0KJ,\u00a0Kovesdy C,\u00a0Langham\u00a0R,\u00a0Rosenberg\u00a0M,\u00a0Jha\u00a0V,\u00a0Zoccali\u00a0C.\u00a0A\u00a0single\u00a0number\u00a0for\u00a0advocacy\u00a0and communication\u2014worldwide more than 850 million individuals have kidney diseases. Kidney Int. <\/i>2019 Nov;96(5):1048\u201350. Available from:\u00a0https:\/\/pubmed.ncbi.nlm.nih.gov\/31582227\/<\/a><\/u><\/span> <\/p>\n<\/td>\n<\/tr>\n

\n

7.\u00a0Centers\u00a0for\u00a0Disease Control\u00a0and\u00a0Prevention\u00a0(CDC).\u00a0Chronic\u00a0Kidney\u00a0Disease:\u00a0Common – Serious\u00a0\u2013\u00a0Costly. Available from: https:\/\/www.cdc.gov\/kidney-disease\/ckd-facts\/index.html.<\/u><\/a><\/u> Last accessed: 30 May 2025.<\/span> <\/p>\n<\/td>\n<\/tr>\n

\n

8.\u00a0Oliveira\u00a0C,\u00a0et\u00a0al.\u00a0Cardiovascular\u00a0Risk\u00a0Factors\u00a0in\u00a0Patients\u00a0with\u00a0Chronic\u00a0Kidney Disease\u00a0Under\u00a0Conservative Treatment. Int J Cardiovasc Sci <\/i>2020;34(2):170-8.<\/span> <\/p>\n<\/td>\n<\/tr>\n

<\/td>\n<\/tr>\n<\/tbody>\n<\/table><\/div>\n

\u00a0<\/p>","protected":false},"excerpt":{"rendered":"

<\/p>\n

SYDNEY<\/span>, June 7, 2025<\/span> \/PRNewswire\/ —\u00a0New modelling highlights the potential societal, economic and environmental benefits of early chronic kidney disease (CKD) intervention which could change lives for thousands of Australians.<\/p>\n

Australia could save $25.2 billion in CKD-related\u00a0costs and\u00a0more\u00a0than halve dialysis demand over 25 years with early action.1<\/sup> The model projects additional gains for the Australian economy\u00a0and\u00a0society with\u00a0projections\u00a0showing a\u00a0$1.6\u00a0billion\u00a0increase\u00a0in\u00a0net\u00a0tax\u00a0revenue\u00a0could be achieved over the same period and 200,000 more people in the workforce.1<\/sup><\/p>\n

An\u00a0estimated\u00a02.7\u00a0million\u00a0people in\u00a0Australia\u00a0are\u00a0currently\u00a0living with\u00a0signs\u00a0of\u00a0CKD.2<\/sup>\u00a0The\u00a0disease costs the Australian economy at least $9.9 billion a year.3<\/sup><\/p>\n

Newly published findings from\u00a0the\u00a0IMPACT CKD\u00a0modelling\u00a0analysis by AstraZeneca\u00a0suggest that policy measures targeting CKD could unlock wide-ranging societal benefits across Australia.\u00a0With\u00a0early\u00a0action pressure\u00a0can\u00a0be\u00a0eased\u00a0on\u00a0the\u00a0healthcare\u00a0system,\u00a0driving\u00a0economic productivity while improving the lives of people living with CKD.<\/p>\n

The\u00a0IMPACT\u00a0CKD\u00a0simulation\u00a0modelled outcomes\u00a0for\u00a0the\u00a0Australian\u00a0population\u00a0over\u00a0a\u00a025-year period, from 2022 to 2047, to explore the potential impact of early intervention.1<\/sup> It assessed the combined effect of earlier detection, diagnosis, and better access to treatment including annual targeted testing for high-risk individuals and improved use of guideline-directed medical therapy (GDMT).<\/p>\n

The modelling projected\u00a0significant improvements\u00a0in health\u00a0outcomes in Australia including\u00a0a 48.1% decrease in cardiovascular (CV) events and a 7.3% decrease in all-cause mortality over\u00a025\u00a0years.1<\/sup>\u00a0These outcomes\u00a0were\u00a0accompanied\u00a0by\u00a0a\u00a055%\u00a0projected\u00a0reduction\u00a0in\u00a0dialysis, one of the most resource-intensive treatment options in CKD care.1<\/sup> As a result, CKD-related healthcare costs in Australia\u00a0are projected to decrease by 10.9%,\u00a0resulting\u00a0in an estimated<\/p>\n

$25.2\u00a0billion in\u00a0savings\u00a0over\u00a0the\u00a0same\u00a0period.1<\/sup><\/p>\n

Beyond the clinical and economic implications, the modelling also indicated that reducing reliance on dialysis could cut kidney replacement therapy (KRT)-related freshwater consumption by\u00a051.0%,\u00a0fossil fuel\u00a0use\u00a0by\u00a048.2%,\u00a0and\u00a0carbon\u00a0emissions by\u00a048.1%1<\/sup>\u00a0–\u00a0delivering meaningful\u00a0environmental\u00a0benefits that\u00a0align\u00a0with\u00a0the\u00a0Australian\u00a0Government’s\u00a0National\u00a0Health and Climate Strategy.<\/p>\n

Ben McDonald, Country President of AstraZeneca Australia and New Zealand, said the findings\u00a0demonstrate\u00a0the\u00a0opportunity\u00a0we\u00a0have\u00a0in\u00a0Australia\u00a0to\u00a0reduce\u00a0the\u00a0health\u00a0and\u00a0economic burden of CKD.<\/p>\n

“Earlier\u00a0access to\u00a0diagnosis\u00a0and\u00a0treatment\u00a0improves outcomes\u00a0for\u00a0patients, can\u00a0slow\u00a0renal progression and help avoid dialysis costs. With the right focus and investment, we can create system-wide benefits for people, society and the planet, Mr McDonald said.<\/p>\n

“Increa<\/span>sing\u00a0the\u00a0early\u00a0detection\u00a0and\u00a0treatment\u00a0of\u00a0CKD\u00a0in\u00a0Australia\u00a0needs\u00a0to\u00a0be\u00a0a\u00a0public health priority. The Australian health system can do more to work with people who are at high risk of having CKD but may not know it.”<\/p>\n

Chris\u00a0Forbes,\u00a0CEO\u00a0of\u00a0Kidney\u00a0Health Australia\u00a0(KHA),\u00a0welcomed the\u00a0findings.<\/p>\n

“Early diagnosis\u00a0can\u00a0make a life-changing difference for Australians living\u00a0with CKD. It’s\u00a0time to\u00a0turn\u00a0off\u00a0the\u00a0tap.\u00a0Early\u00a0detection\u00a0provides\u00a0patients\u00a0the\u00a0best\u00a0opportunity\u00a0to\u00a0treat\u00a0the\u00a0disease – slowing or even stopping progression to kidney failure, and avoiding the significant toll of dialysis, Mr Forbes said.<\/p>\n

“Too many people are slipping through the cracks until it’s too late. Our ambition is a future where every Australian has the ability to enjoy excellent kidney health. We urgently need policy action to support earlier detection and timely access to treatment.”<\/p>\n

NOT<\/span>ES TO EDITORS<\/u> <\/b> <\/p>\n

IMPACT CKD is the first study to examine and forecast the vast impact of CKD over a 25- year\u00a0time\u00a0horizon.1<\/sup>\u00a0It is\u00a0based\u00a0on\u00a0a\u00a0conceptual\u00a0disease\u00a0framework\u00a0developed\u00a0by\u00a0researchers at the London School of Economics in consultation with over 60 international and Australian experts. IMPACT CKD is part of AstraZeneca’s aim to improve the understanding and outcomes of CKD worldwide. AstraZeneca and\u00a0the Global Patient Alliance for Kidney Health (GloPAKH) launched ‘Make the Change for Kidney Health’<\/a> campaign to educate policy makers and health system leaders. This initiative seeks to elevate CKD on the global policy agenda, advocating for comprehensive and effective disease management strategies to combat this escalating health challenge.<\/p>\n

The new IMPACT CKD findings come just days after the World Health Assembly adopted a new\u00a0resolution\u00a0recognising\u00a0CKD\u00a0as\u00a0a\u00a0global public\u00a0health\u00a0priority which\u00a0is\u00a0a\u00a0critical\u00a0milestone that elevates CKD to the level of other major non-communicable diseases such as cancer, cardiovascular disease, and diabetes.4<\/sup><\/p>\n

About\u00a0CKD<\/b> <\/p>\n

CKD\u00a0is\u00a0a\u00a0silent disease\u00a0until\u00a0a\u00a0late\u00a0stage.5<\/sup>\u00a0Nearly\u00a0850\u00a0million people worldwide6<\/sup>, and\u00a0an estimated 2.7 million people in Australia have biomarkers of CKD, with 2.5 million<\/p>\n

Australians undiagnosed and unaware they have signs of the disease.2<\/sup> The most common causes\u00a0of\u00a0CKD\u00a0include\u00a0diabetes and\u00a0hypertension.\u00a0CKD\u00a0is\u00a0associated\u00a0with\u00a0significant\u00a0patient morbidity and an increased risk of cardiovascular events, such as myocardial infarction and heart failure (HF), which drives premature death.7<\/sup> In its most severe form, known as kidney failure, kidney damage and deterioration of kidney function have progressed to the point where dialysis or kidney transplantation are required. CKD patients are more likely to die of CV disease than to progress to end stage kidney disease.8<\/sup><\/p>\n

\n\n\n\n\n\n\n\n\n\n\n\n\n\n
<\/td>\n<\/tr>\n
\n

References<\/b> <\/span> <\/p>\n<\/td>\n<\/tr>\n

\n

1.\u00a0Tangri\u00a0N,\u00a0et\u00a0al.\u00a0Impact of\u00a0improved\u00a0diagnosis\u00a0and\u00a0treatment\u00a0on\u00a0holistic\u00a0chronic kidney\u00a0disease\u00a0burden. Kidney Int Rep<\/i>. 2025. In press. Journal Pre-proof. doi:10.1016\/j.ekir.2025.05.039.<\/span> <\/p>\n<\/td>\n<\/tr>\n

\n

2. ABS\u00a0National\u00a0Health\u00a0Measures Survey,\u00a0https:\/\/www.abs.gov.au\/statistics\/health\/health-conditions-and-<\/a><\/u>\u00a0risks\/national-health-measures-survey\/2022-24<\/a><\/u>\u00a0viewed\u00a030\u00a0May\u00a02025,\u00a0and\u00a0Kidney Health\u00a0Australia,\u00a0Media Release, ‘Kidney Disease Crisis: 2.7 million Australians Affected, 7 April 2025.<\/span> <\/p>\n<\/td>\n<\/tr>\n

\n

3.\u00a0Kidney\u00a0Health\u00a0Australia\u00a0and\u00a0Deloitte\u00a0Access Economics, Changing\u00a0the\u00a0chronic kidney\u00a0disease\u00a0landscape:\u00a0The economic benefits of early detection and treatment<\/i>, February 2023, https:\/\/kidney.org.au\/get-<\/a><\/u>\u00a0involved\/advocacy\/deloittereport<\/a>, <\/u>viewed 30 May 2025.<\/span> <\/p>\n<\/td>\n<\/tr>\n

\n

4.\u00a0World Health Organization (WHO). Seventy-eighth World Health Assembly \u2013 Daily update: 23 May 2025. Available\u00a0from:\u00a0https:\/\/www.who.int\/news\/item\/23-05-2025-seventy-eighth-world-health-assembly—daily-update–<\/a><\/u>\u00a023-may-2025,<\/u><\/a><\/u> viewed 30 May 2025.<\/span> <\/p>\n<\/td>\n<\/tr>\n

\n

5.\u00a0Whaley-Connell\u00a0A,\u00a0et\u00a0al.\u00a0The\u00a0importance\u00a0of\u00a0early identification\u00a0of\u00a0chronic kidney\u00a0disease.\u00a0Mo\u00a0Med.\u00a02011\u00a0Jan- Feb;108(1):25\u20138. PMID: 21462606; PMCID: PMC6188457.<\/span> <\/p>\n<\/td>\n<\/tr>\n

\n

6.\u00a0Jager\u00a0KJ,\u00a0Kovesdy C,\u00a0Langham\u00a0R,\u00a0Rosenberg\u00a0M,\u00a0Jha\u00a0V,\u00a0Zoccali\u00a0C.\u00a0A\u00a0single\u00a0number\u00a0for\u00a0advocacy\u00a0and communication\u2014worldwide more than 850 million individuals have kidney diseases. Kidney Int. <\/i>2019 Nov;96(5):1048\u201350. Available from:\u00a0https:\/\/pubmed.ncbi.nlm.nih.gov\/31582227\/<\/a><\/u><\/span> <\/p>\n<\/td>\n<\/tr>\n

\n

7.\u00a0Centers\u00a0for\u00a0Disease Control\u00a0and\u00a0Prevention\u00a0(CDC).\u00a0Chronic\u00a0Kidney\u00a0Disease:\u00a0Common – Serious\u00a0\u2013\u00a0Costly. Available from: https:\/\/www.cdc.gov\/kidney-disease\/ckd-facts\/index.html.<\/u><\/a><\/u> Last accessed: 30 May 2025.<\/span> <\/p>\n<\/td>\n<\/tr>\n

\n

8.\u00a0Oliveira\u00a0C,\u00a0et\u00a0al.\u00a0Cardiovascular\u00a0Risk\u00a0Factors\u00a0in\u00a0Patients\u00a0with\u00a0Chronic\u00a0Kidney Disease\u00a0Under\u00a0Conservative Treatment. Int J Cardiovasc Sci <\/i>2020;34(2):170-8.<\/span> <\/p>\n<\/td>\n<\/tr>\n

<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n

\u00a0<\/p>\n

<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":[],"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[5,7],"tags":[],"class_list":["post-25071","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cision-pr-newswire","category-cision-pr-newswire-en"],"_links":{"self":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/25071","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=25071"}],"version-history":[{"count":0,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/25071\/revisions"}],"wp:attachment":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=25071"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=25071"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=25071"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}